North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Results
Looking for
Nivolumab
found
25 matches
Formulary items
2 matches
Open monograph to display formulary status
BNF Category
Nivolumab
(Opdivo
®
)
Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
Ipilimumab
(Yervoy
®
)
Malignant disease and immunosuppression - Ipilimumab - 08.01.05
Links
Link to Drug Section
Link to document
MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection (08.01.05)
MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection (08.01.05)
MHRA Drug Safety Update (Oct 2019): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (08.01.05)
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma (08.01.05)
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma (08.01.05)
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma (08.01.05)
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma (08.01.05)
NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (08.01.05)
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (08.01.05)
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (08.01.05)
NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (08.01.05)
NICE TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (08.01.05)
NICE TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (08.01.05)
NICE TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (08.01.05)
NICE TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small- cell lung cancer (08.01.05)
NICE TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (08.01.05)
NICE TA746: Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (08.01.05)
NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (08.01.05)
NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (08.01.05)
NICE TA817: Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (08.01.05)
NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (08.01.05)
NICE TA865: Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (08.01.05)
NICE TA876: Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (08.01.05)